To test whether or not the short survival of patients from the short-lived subgroup is mainly driven by FLT3-NPM1 co-mutations, we separately analyzed a subset of in total 29 AML patients from the TCGA AML cohort, which had these two genes mutated. This evidence concerns the gene NPM1 and acute myeloid leukemia.